Replies to post #106978 on Biotech Values

[dewophile]

out of curiosity what do you think the royalty case will be in the event tL is approved?

i think previous estimates of 30M annually bandied about on this board are low - mL will still have first mover advantage, pricing imo will only drop another 10-15% for a total discount to branded of around 25-30% (after all we are still talking about limited generic entrants), and a market that appears to still be growing